AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced it will be featured as a presenting company at the H.C. Wainwright Global Life Sciences Conference, a virtual conference held March 9-10, 2021. The Company will showcase an updated Investor Presentation and discuss some of its new technology. Darrell Dotson, Vice President and General Counsel, of AIkido Pharma Inc. will present for the Company.
If you are an institutional investor, and would like to attend the Company's presentation, please click on the following link (https://hcwevents.com/globalconference/) to register for the conference.
About H.C. Wainwright
H.C. Wainwright is a full–service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. H.C. Wainwright & Co. also provides research and sales and trading services to institutional investors. According to Sagient Research Systems, H.C. Wainwright's team is ranked as the #1 Placement Agent in terms of aggregate CMPO (confidentially marketed public offering), RD (registered direct offering) and PIPE (private investment in public equity) executed cumulatively since 1998.
About AIkido Pharma Inc.
AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company's platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.
Contact:
Investor Relations:
Hayden IR
Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com
AIkido Pharma Inc.:
Phone: 212-745-1373
Email: investorrelations@aikidopharma.com
www.aikidopharma.com
Aikido Pharma Has Licensed DHA-dFdC at The University of Texas at Austin
Released On: 3/5/2021
Views: 899
Aikido Pharma Shares Published Papers and Articles on KPC-34 and DHA-dFdC
Released On: 3/3/2021
Views: 875
Aikido Pharma Announces Findings of Positive Results From New Drug “DHA-dFdC” Developed at The University of Texas at Austin
Released On: 3/1/2021
Views: 914
AIkido Pharma Inc. to Present at the H.C. Wainwright Global Life Sciences Conference (Virtual Event)
Released On: 3/1/2021
Views: 1320
Meet Aikido Pharma Inc’s Board of Directors
Released On: 2/28/2021
Views: 927
AIkido Pharma Inc. Announces Exercise of Option to Purchase Additional Shares in Bought Deal Offering
Released On: 2/23/2021
Views: 953
Artificial Intelligence Is Optimizing Drug Development
Released On: 2/22/2021
Views: 976
Aikido Pharma Focuses on The Treatment of Four Main Types of Cancer
Released On: 2/20/2021
Views: 863
AIkido Pharma Inc. Announces Closing of $75 Million Bought Deal Offering of Common Stock
Released On: 2/19/2021
Views: 1016
AIkido Pharma Inc. Increases Previously Announced Bought Deal Offering of Common Stock to $75 Million
Released On: 2/16/2021
Views: 1111
AIkido Pharma Inc. Announces $10 Million Bought Deal Offering Of Common Stock
Released On: 2/16/2021
Views: 1062
AIkido Pharma Enters Into Letter Of Intent With Silo Pharma for Use of Psilocybin and Peptide Therapy for Cancer Treatment
Released On: 2/16/2021
Views: 1195
Aikido Pharma Announces Information on KPC-34 Which Was Developed at the Wake Forest School of Medicine
Released On: 2/15/2021
Views: 859
Aikido Pharma Establishes Licensing Agreement with University of Maryland
for Antiviral Compounds, Including COVID-19
Released On: 2/10/2021
Views: 772
Aikido Pharma Announces DHA-dFdC Which Is Licensed From the University of Texas at Austin for the treatment of Pancreatic Cancer.
Released On: 2/9/2021
Views: 1366
Aikido Pharma Secures Early Interest in Convergent Therapeutics, Inc. Who Focuses On Next Generation Radiopharmaceutical Therapy for Prostate Cancer
Released On: 2/5/2021
Views: 941
AIkido Pharma Appoints Dr. Scott T. Tagawa, M.D. to Scientific Advisory Board
Released On: 2/3/2021
Views: 1827
Meet Aikido Pharma A BioTechnology Development Company Focused on The Treatment Of Early and Mid-Stage Small-Molecule Anti-Cancer Therapeutics
Released On: 2/3/2021
Views: 1040